Article Contents ::
- 1 Details About Generic Salt :: Dextroam
- 2 Main Medicine Class:: CNS stimulant, Amphetamine
- 3
(DEX-troe-am-FET-uh-meen SULL-fate)
Dexedrine
Tablets
5 mg
Dexedrine Spansules
Capsules, sustained-release
5 mg
Capsules, sustained-release
10 mg
Capsules, sustained-release
15 mg
DextroStat
Tablets
5 mg
Class: CNS stimulant, Amphetamine
Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.
Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.
Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.
Route/Dosage
Narcolepsy
Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.
Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.
Attention Deficit Disorder
Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Exogenous Obesity
Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.
Interactions
Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.
Lab Test Interferences Plasma and urinary steroid levels may be altered.
Adverse Reactions
CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.
PATIENT CARE CONSIDERATIONS
Administration/Storage
Limit patient’s access to medication.
Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
Do not crush or open sustained-release tablets.
Assessment/Interventions
Obtain patient history, including drug history and any known allergies.
Assess baseline nutritional status.
Document any abnormal behavior.
Document monthly measurement of physical growth in children.
Document weight weekly.
Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
OVERDOSAGE: SIGNS & SYMPTOMS
Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps
Patient/Family Education
Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
Tell patient to record body weight weekly.
Instruct patient/family to measure height monthly if patient is child.
Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Dextroam
| (DEX-troe-am-FET-uh-meen SULL-fate) |
| Dexedrine |
| Tablets |
| 5 mg |
| Dexedrine Spansules |
| Capsules, sustained-release |
| 5 mg |
| Capsules, sustained-release |
| 10 mg |
| Capsules, sustained-release |
| 15 mg |
| DextroStat |
| Tablets |
| 5 mg |
| Class: CNS stimulant, Amphetamine |
Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.
Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.
Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.
Route/Dosage
Narcolepsy
Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.
Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.
Attention Deficit Disorder
Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Exogenous Obesity
Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.
Interactions
Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.
Lab Test Interferences Plasma and urinary steroid levels may be altered.
Adverse Reactions
CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Limit patient’s access to medication.
- Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
- Do not crush or open sustained-release tablets.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Assess baseline nutritional status.
- Document any abnormal behavior.
- Document monthly measurement of physical growth in children.
- Document weight weekly.
- Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps |
|
Patient/Family Education
- Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
- Tell patient to record body weight weekly.
- Instruct patient/family to measure height monthly if patient is child.
- Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
- Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
- Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.
Drugs Class ::
| (DEX-troe-am-FET-uh-meen SULL-fate) |
| Dexedrine |
| Tablets |
| 5 mg |
| Dexedrine Spansules |
| Capsules, sustained-release |
| 5 mg |
| Capsules, sustained-release |
| 10 mg |
| Capsules, sustained-release |
| 15 mg |
| DextroStat |
| Tablets |
| 5 mg |
| Class: CNS stimulant, Amphetamine |
Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.
Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.
Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.
Route/Dosage
Narcolepsy
Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.
Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.
Attention Deficit Disorder
Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Exogenous Obesity
Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.
Interactions
Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.
Lab Test Interferences Plasma and urinary steroid levels may be altered.
Adverse Reactions
CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Limit patient’s access to medication.
- Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
- Do not crush or open sustained-release tablets.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Assess baseline nutritional status.
- Document any abnormal behavior.
- Document monthly measurement of physical growth in children.
- Document weight weekly.
- Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps |
|
Patient/Family Education
- Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
- Tell patient to record body weight weekly.
- Instruct patient/family to measure height monthly if patient is child.
- Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
- Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
- Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.
Indications for Drugs ::
| (DEX-troe-am-FET-uh-meen SULL-fate) |
| Dexedrine |
| Tablets |
| 5 mg |
| Dexedrine Spansules |
| Capsules, sustained-release |
| 5 mg |
| Capsules, sustained-release |
| 10 mg |
| Capsules, sustained-release |
| 15 mg |
| DextroStat |
| Tablets |
| 5 mg |
| Class: CNS stimulant, Amphetamine |
Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.
Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.
Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.
Route/Dosage
Narcolepsy
Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.
Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.
Attention Deficit Disorder
Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Exogenous Obesity
Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.
Interactions
Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.
Lab Test Interferences Plasma and urinary steroid levels may be altered.
Adverse Reactions
CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Limit patient’s access to medication.
- Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
- Do not crush or open sustained-release tablets.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Assess baseline nutritional status.
- Document any abnormal behavior.
- Document monthly measurement of physical growth in children.
- Document weight weekly.
- Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps |
|
Patient/Family Education
- Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
- Tell patient to record body weight weekly.
- Instruct patient/family to measure height monthly if patient is child.
- Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
- Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
- Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.
Drug Dose ::
| (DEX-troe-am-FET-uh-meen SULL-fate) |
| Dexedrine |
| Tablets |
| 5 mg |
| Dexedrine Spansules |
| Capsules, sustained-release |
| 5 mg |
| Capsules, sustained-release |
| 10 mg |
| Capsules, sustained-release |
| 15 mg |
| DextroStat |
| Tablets |
| 5 mg |
| Class: CNS stimulant, Amphetamine |
Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.
Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.
Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.
Route/Dosage
Narcolepsy
Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.
Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.
Attention Deficit Disorder
Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Exogenous Obesity
Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.
Interactions
Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.
Lab Test Interferences Plasma and urinary steroid levels may be altered.
Adverse Reactions
CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Limit patient’s access to medication.
- Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
- Do not crush or open sustained-release tablets.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Assess baseline nutritional status.
- Document any abnormal behavior.
- Document monthly measurement of physical growth in children.
- Document weight weekly.
- Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps |
|
Patient/Family Education
- Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
- Tell patient to record body weight weekly.
- Instruct patient/family to measure height monthly if patient is child.
- Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
- Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
- Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.
Contraindication ::
| (DEX-troe-am-FET-uh-meen SULL-fate) |
| Dexedrine |
| Tablets |
| 5 mg |
| Dexedrine Spansules |
| Capsules, sustained-release |
| 5 mg |
| Capsules, sustained-release |
| 10 mg |
| Capsules, sustained-release |
| 15 mg |
| DextroStat |
| Tablets |
| 5 mg |
| Class: CNS stimulant, Amphetamine |
Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.
Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.
Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.
Route/Dosage
Narcolepsy
Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.
Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.
Attention Deficit Disorder
Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Exogenous Obesity
Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.
Interactions
Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.
Lab Test Interferences Plasma and urinary steroid levels may be altered.
Adverse Reactions
CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Limit patient’s access to medication.
- Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
- Do not crush or open sustained-release tablets.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Assess baseline nutritional status.
- Document any abnormal behavior.
- Document monthly measurement of physical growth in children.
- Document weight weekly.
- Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps |
|
Patient/Family Education
- Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
- Tell patient to record body weight weekly.
- Instruct patient/family to measure height monthly if patient is child.
- Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
- Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
- Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.
Drug Precautions ::
| (DEX-troe-am-FET-uh-meen SULL-fate) |
| Dexedrine |
| Tablets |
| 5 mg |
| Dexedrine Spansules |
| Capsules, sustained-release |
| 5 mg |
| Capsules, sustained-release |
| 10 mg |
| Capsules, sustained-release |
| 15 mg |
| DextroStat |
| Tablets |
| 5 mg |
| Class: CNS stimulant, Amphetamine |
Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.
Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.
Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.
Route/Dosage
Narcolepsy
Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.
Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.
Attention Deficit Disorder
Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Exogenous Obesity
Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.
Interactions
Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.
Lab Test Interferences Plasma and urinary steroid levels may be altered.
Adverse Reactions
CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Limit patient’s access to medication.
- Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
- Do not crush or open sustained-release tablets.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Assess baseline nutritional status.
- Document any abnormal behavior.
- Document monthly measurement of physical growth in children.
- Document weight weekly.
- Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps |
|
Patient/Family Education
- Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
- Tell patient to record body weight weekly.
- Instruct patient/family to measure height monthly if patient is child.
- Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
- Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
- Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.
Drug Side Effects ::
| (DEX-troe-am-FET-uh-meen SULL-fate) |
| Dexedrine |
| Tablets |
| 5 mg |
| Dexedrine Spansules |
| Capsules, sustained-release |
| 5 mg |
| Capsules, sustained-release |
| 10 mg |
| Capsules, sustained-release |
| 15 mg |
| DextroStat |
| Tablets |
| 5 mg |
| Class: CNS stimulant, Amphetamine |
Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.
Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.
Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.
Route/Dosage
Narcolepsy
Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.
Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.
Attention Deficit Disorder
Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Exogenous Obesity
Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.
Interactions
Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.
Lab Test Interferences Plasma and urinary steroid levels may be altered.
Adverse Reactions
CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Limit patient’s access to medication.
- Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
- Do not crush or open sustained-release tablets.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Assess baseline nutritional status.
- Document any abnormal behavior.
- Document monthly measurement of physical growth in children.
- Document weight weekly.
- Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps |
|
Patient/Family Education
- Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
- Tell patient to record body weight weekly.
- Instruct patient/family to measure height monthly if patient is child.
- Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
- Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
- Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.
Drug Mode of Action ::
| (DEX-troe-am-FET-uh-meen SULL-fate) |
| Dexedrine |
| Tablets |
| 5 mg |
| Dexedrine Spansules |
| Capsules, sustained-release |
| 5 mg |
| Capsules, sustained-release |
| 10 mg |
| Capsules, sustained-release |
| 15 mg |
| DextroStat |
| Tablets |
| 5 mg |
| Class: CNS stimulant, Amphetamine |
Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.
Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.
Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.
Route/Dosage
Narcolepsy
Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.
Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.
Attention Deficit Disorder
Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Exogenous Obesity
Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.
Interactions
Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.
Lab Test Interferences Plasma and urinary steroid levels may be altered.
Adverse Reactions
CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Limit patient’s access to medication.
- Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
- Do not crush or open sustained-release tablets.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Assess baseline nutritional status.
- Document any abnormal behavior.
- Document monthly measurement of physical growth in children.
- Document weight weekly.
- Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps |
|
Patient/Family Education
- Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
- Tell patient to record body weight weekly.
- Instruct patient/family to measure height monthly if patient is child.
- Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
- Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
- Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.
Drug Interactions ::
| (DEX-troe-am-FET-uh-meen SULL-fate) |
| Dexedrine |
| Tablets |
| 5 mg |
| Dexedrine Spansules |
| Capsules, sustained-release |
| 5 mg |
| Capsules, sustained-release |
| 10 mg |
| Capsules, sustained-release |
| 15 mg |
| DextroStat |
| Tablets |
| 5 mg |
| Class: CNS stimulant, Amphetamine |
Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.
Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.
Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.
Route/Dosage
Narcolepsy
Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.
Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.
Attention Deficit Disorder
Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Exogenous Obesity
Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.
Interactions
Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.
Drug Assesment ::
| (DEX-troe-am-FET-uh-meen SULL-fate) |
| Dexedrine |
| Tablets |
| 5 mg |
| Dexedrine Spansules |
| Capsules, sustained-release |
| 5 mg |
| Capsules, sustained-release |
| 10 mg |
| Capsules, sustained-release |
| 15 mg |
| DextroStat |
| Tablets |
| 5 mg |
| Class: CNS stimulant, Amphetamine |
Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.
Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.
Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.
Route/Dosage
Narcolepsy
Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.
Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.
Attention Deficit Disorder
Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Exogenous Obesity
Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.
Interactions
Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.
Lab Test Interferences Plasma and urinary steroid levels may be altered.
Adverse Reactions
CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Limit patient’s access to medication.
- Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
- Do not crush or open sustained-release tablets.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Assess baseline nutritional status.
- Document any abnormal behavior.
- Document monthly measurement of physical growth in children.
- Document weight weekly.
- Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps |
|
Patient/Family Education
- Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
- Tell patient to record body weight weekly.
- Instruct patient/family to measure height monthly if patient is child.
- Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
- Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
- Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.
Drug Storage/Management ::
| (DEX-troe-am-FET-uh-meen SULL-fate) |
| Dexedrine |
| Tablets |
| 5 mg |
| Dexedrine Spansules |
| Capsules, sustained-release |
| 5 mg |
| Capsules, sustained-release |
| 10 mg |
| Capsules, sustained-release |
| 15 mg |
| DextroStat |
| Tablets |
| 5 mg |
| Class: CNS stimulant, Amphetamine |
Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.
Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.
Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.
Route/Dosage
Narcolepsy
Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.
Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.
Attention Deficit Disorder
Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Exogenous Obesity
Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.
Interactions
Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.
Lab Test Interferences Plasma and urinary steroid levels may be altered.
Adverse Reactions
CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Limit patient’s access to medication.
- Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
- Do not crush or open sustained-release tablets.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Assess baseline nutritional status.
- Document any abnormal behavior.
- Document monthly measurement of physical growth in children.
- Document weight weekly.
- Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps |
|
Patient/Family Education
- Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
- Tell patient to record body weight weekly.
- Instruct patient/family to measure height monthly if patient is child.
- Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
- Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
- Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.
Drug Notes ::
| (DEX-troe-am-FET-uh-meen SULL-fate) |
| Dexedrine |
| Tablets |
| 5 mg |
| Dexedrine Spansules |
| Capsules, sustained-release |
| 5 mg |
| Capsules, sustained-release |
| 10 mg |
| Capsules, sustained-release |
| 15 mg |
| DextroStat |
| Tablets |
| 5 mg |
| Class: CNS stimulant, Amphetamine |
Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.
Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.
Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.
Route/Dosage
Narcolepsy
Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.
Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.
Attention Deficit Disorder
Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.
Exogenous Obesity
Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.
Interactions
Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.
Lab Test Interferences Plasma and urinary steroid levels may be altered.
Adverse Reactions
CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Limit patient’s access to medication.
- Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
- Do not crush or open sustained-release tablets.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Assess baseline nutritional status.
- Document any abnormal behavior.
- Document monthly measurement of physical growth in children.
- Document weight weekly.
- Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps |
|
Patient/Family Education
- Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
- Tell patient to record body weight weekly.
- Instruct patient/family to measure height monthly if patient is child.
- Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
- Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
- Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.
Disclaimer ::
The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
